Associated tags: Regenerative Medicine Advanced Therapy, Engineering, Acute myeloid leukemia, Cancer, Multiple myeloma, Regenerative medicine, Patient, Medicine, Food, Pharmaceutical industry, Webcast, Conference
Locations: UNITED STATES, NORTH AMERICA, CALIFORNIA
Stem Cells,
Biotechnology,
FDA,
Health,
General Health,
Pharmaceutical,
Oncology,
Research,
Hospitals,
Science,
Clinical Trials,
Multiple myeloma,
Safety,
Food,
IND,
Patient,
SOC,
Standard of care,
BCMA,
Investigational New Drug,
Pharmaceutical industry Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program.
Key Points:
- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program.
- Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
- The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year.
- In addition, the completion of the technical transfer to Kite allowed us to accelerate our development program and launch iMMagine-3 globally, which will enable broader and earlier patient access to anito-cel.”
Research,
FDA,
Clinical Trials,
Other Health,
Biotechnology,
General Health,
Pharmaceutical,
Health,
Science,
Other Science,
Multiple myeloma,
GILD,
Safety,
Food,
IND,
Patient,
SOC,
Standard of care,
BCMA,
Investigational New Drug,
Pharmaceutical industry Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program.
Key Points:
- Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program.
- Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
- The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year.
- We know manufacturing quality, reliability, and speed are critically important as every day matters for these patients.”
Oncology,
Health,
Stem Cells,
Genetics,
Pharmaceutical,
Biotechnology,
Collaboration,
Research,
Lonza,
Cancer,
Kite,
Patient,
Pharmaceutical industry Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024.
Key Points:
- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024.
- As of March 31, 2024, Arcellx had cash, cash equivalents, and marketable securities of $691.0 million.
- Collaboration revenue were $39.3 million and $17.9 million for the quarters ended March 31, 2024 and 2023, respectively, an increase of $21.4 million.
- Net loss was $7.2 million and $27.3 million for the quarters ended March 31, 2024 and 2023, respectively.
Research,
Clinical Trials,
Stem Cells,
Other Health,
Biotechnology,
Pharmaceutical,
Health,
Science,
Oncology,
Other Science,
Cancer,
Patient,
Fireside chats,
Communications satellite Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in two upcoming investor conferences:
Key Points:
- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in two upcoming investor conferences:
Presentation: Tuesday, May 14 at 3:40 p.m. PT
Fireside Chat: Tuesday, May 28 at 1:00 p.m. PT
A live webcast of these discussions will be accessible from Arcellx’s website at www.arcellx.com in the Investors section.
- A replay of the webcasts will be archived and available for 30 days following the event.
Infectious Diseases,
Clinical Trials,
Stem Cells,
Biotechnology,
Other Health,
Health,
Other Science,
Science,
Oncology,
Webcast,
Patient,
Conference,
Cancer Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m.
Key Points:
- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m.
- ET.
- A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section.
- A replay of the webcast will be archived and available for 30 days following the event.
Retrieved on:
Wednesday, March 20, 2024
Stem Cells,
Biotechnology,
Other Health,
Health,
General Health,
Pharmaceutical,
Oncology,
Other Science,
Research,
Science,
Clinical Trials,
Webcast,
Patient,
Conference,
Cancer Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m.
Key Points:
- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m.
- ET.
- A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section.
- A replay of the webcast will be archived and available for 30 days following the event.
Retrieved on:
Thursday, February 29, 2024
REDWOOD CITY, Calif., Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, at 2:50 p.m.
Key Points:
- REDWOOD CITY, Calif., Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, at 2:50 p.m.
- ET.
- A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section.
- A replay of the webcast will be archived and available for 30 days following the event.
Retrieved on:
Wednesday, November 15, 2023
Research,
Hospitals,
Genetics,
Clinical Trials,
Biotechnology,
Health,
Pharmaceutical,
Science,
Oncology,
Multiple myeloma,
Economics,
Sparx,
ASH,
Patient,
EPS,
IPR,
Cancer,
Partnership,
Lymphoma,
BCMA,
Hart–Scott–Rodino Antitrust Improvements Act,
Pharmaceutical industry,
Kite “Given this, we are deepening our relationship with Arcellx to further support advancement of CART-ddBCMA, bolster our pipeline in multiple myeloma, as well as access opportunities in lymphoma.
Key Points:
- “Given this, we are deepening our relationship with Arcellx to further support advancement of CART-ddBCMA, bolster our pipeline in multiple myeloma, as well as access opportunities in lymphoma.
- In expanding our strategic partnership with Arcellx, we are building upon the established synergy between Arcellx’s platform technologies and Kite’s industry-leading position in CAR T manufacturing and commercialization."
- “Since entering into this strategic collaboration with Kite almost one year ago, we are thrilled with how the partnership is rapidly progressing and the alignment across our teams,” said Rami Elghandour, Arcellx’s Chairman and Chief Executive Officer.
- Importantly, these efficiencies embody the trust developed with our Kite partners and do not alter the original agreement in principle or economics.
Retrieved on:
Thursday, October 26, 2023
REDWOOD CITY, Calif., Oct. 26, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that the management team will participate in two upcoming investor conferences:
Key Points:
- REDWOOD CITY, Calif., Oct. 26, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that the management team will participate in two upcoming investor conferences:
Fireside Chat: Friday, November 3 at 12:30 p.m.
- ET
Fireside Chat: Wednesday, November 15 at 1:15 p.m.
- ET
A live webcast of these discussions will be accessible from Arcellx's website at www.arcellx.com in the Investors section.
- A replay of the webcasts will be archived and available for 30 days following the event.
REDWOOD CITY, Calif., April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023, at 1:00 p.m.
Key Points:
- REDWOOD CITY, Calif., April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023, at 1:00 p.m.
- ET.
- A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section.
- A replay of the webcast will be archived and available for 30 days following the event.
